Affinage

FIP1L1

Pre-mRNA 3'-end-processing factor FIP1 · UniProt Q6UN15

Length
594 aa
Mass
66.5 kDa
Annotated
2026-06-09
100 papers in source corpus 27 papers cited in narrative 27 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FIP1L1 encodes hFip1, an intrinsically disordered, multivalent scaffold subunit of the cleavage and polyadenylation specificity factor (CPSF) that couples poly(A) polymerase (PAP) to pre-mRNA 3'-end processing (PMID:14749727, PMID:7736590). hFip1 directly binds PAP and an arginine-rich motif preferentially recognizes U-rich pre-mRNA elements, and recombinant hFip1 is sufficient to stimulate PAP polyadenylation activity in a U-rich-element-dependent manner (PMID:14749727). Within CPSF, two copies of hFip1 are tethered through the ZF4 and ZF5 zinc fingers of CPSF30, and these copies act redundantly to recruit PAP and increase polyadenylation processivity, while an N-terminal acidic motif of hFip1 binds CstF77 to competitively modulate PAP recruitment (PMID:33122294, PMID:36073787). The disordered linker connecting the CPSF-anchoring and PAP-binding sites remains highly dynamic within the assembled complex, consistent with a flexible-tether mechanism that positions PAP near RNA (PMID:21282348, PMID:34593603). Through control of alternative polyadenylation, hFip1 is essential for embryonic stem cell self-renewal and somatic reprogramming (PMID:24596251) and drives 3'UTR shortening of NLRP3 mRNA to amplify inflammation under oxidative stress (PMID:34011928). Independently, FIP1L1 is the N-terminal partner of the FIP1L1-PDGFRα fusion generated by a chromosome 4q12 deletion, a constitutively active tyrosine kinase that transforms hematopoietic cells and is inhibited by imatinib, with the T674I and D842V kinase-domain mutations conferring resistance (PMID:12660384, PMID:19212337); this fusion underlies a myeloproliferative/chronic eosinophilic leukemia phenotype. Constitutive activation arises from disruption of the PDGFRα juxtamembrane autoinhibitory domain rather than from FIP1L1 itself, which is dispensable for kinase activation (PMID:16690743). The fusion escapes ubiquitination and proteasomal degradation, and signals through PI3K/ERK/STAT5, JAK2, SHP2, and NF-κB to drive eosinophil lineage commitment via C/EBPα and GATA-2 (PMID:17440089, PMID:19644140, PMID:19147501, PMID:24618081).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 1995 High

    Established the founding mechanism: Fip1 physically links poly(A) polymerase to the 3'-end processing machinery, answering how PAP is recruited and made substrate-specific.

    Evidence Two-hybrid, in vitro reconstitution of a 1:1 Fip1-Pap1 complex, ts-mutant and 3'-processing assays in yeast

    PMID:7736590

    Open questions at the time
    • Structural basis of the Fip1-Pap1 interface not defined
    • Human ortholog function not yet shown
  2. 2001 High

    Dissected Fip1 into discrete functional domains, showing it both inhibits and directs PAP activity through separable Pap1-binding, Yth1-binding, and RNA-restricting regions.

    Evidence Domain deletion mutagenesis, in vitro polyadenylation, and yeast viability assays

    PMID:11238938

    Open questions at the time
    • Mechanism by which the C-terminus relieves repression not structurally resolved
    • In vivo relevance of individual domains in mammals untested
  3. 2003 High

    Revealed an entirely distinct disease-driving role: a 4q12 deletion fuses FIP1L1 to PDGFRA to create a constitutively active, imatinib-sensitive kinase, defining the molecular basis of a myeloproliferative disease.

    Evidence Chromosomal analysis, RT-PCR, Ba/F3 transformation, in vitro kinase inhibition; plus murine BMT model with PKC412

    PMID:12660384 PMID:12781364

    Open questions at the time
    • Contribution of the FIP1L1 portion to activation not yet resolved
    • Resistance mechanisms beyond T674I unknown
  4. 2004 High

    Identified human hFip1 as an integral CPSF subunit that binds PAP and U-rich RNA and stimulates polyadenylation, establishing functional conservation of the yeast mechanism in humans.

    Evidence Co-IP, recombinant in vitro polyadenylation, RNA-binding and ternary complex reconstitution

    PMID:14749727

    Open questions at the time
    • Stoichiometry within CPSF not determined
    • Genome-wide targets and APA roles unaddressed
  5. 2006 High

    Resolved that FIP1L1-PDGFRα activation derives from loss of the PDGFRα juxtamembrane autoinhibition, not from FIP1L1, clarifying the oncogenic mechanism.

    Evidence Deletion mutagenesis, in vitro kinase assay, cell transformation, murine BMT

    PMID:16690743

    Open questions at the time
    • Why the fusion is favored over other JM-disrupting events not addressed
    • Role of FIP1L1 sequences in fine-tuning signaling left open
  6. 2006 Medium

    Identified CK2 as a kinase phosphorylating yeast Fip1, raising the possibility of post-translational regulation of polyadenylation.

    Evidence In vitro CK2 kinase assay with MALDI-MS site identification

    PMID:16496213

    Open questions at the time
    • Functional consequence of S73/S77 phosphorylation not established
    • Phosphorylation not demonstrated in vivo
  7. 2007 High

    Mapped the proliferative signaling output of FIP1L1-PDGFRα to PI3K, ERK1/2, and STAT5 in primary human progenitors, defining therapeutically relevant nodes.

    Evidence CD34+ retroviral transduction, dominant-negative STAT5, PI3K/ERK inhibitors, colony assays; c-Myc via ERK/JNK in EOL-1

    PMID:17440089 PMID:18086564

    Open questions at the time
    • Relative contribution of each pathway to in vivo disease unclear
    • Connection between signaling and lineage choice not yet made
  8. 2008 High

    Provided the structural basis of Fip1-PAP recognition and confirmed Fip1 is intrinsically disordered absent its partner.

    Evidence X-ray crystallography of Pap1-Fip1(80-105), structure-guided mutagenesis, yeast viability, CD and ultracentrifugation

    PMID:18537269

    Open questions at the time
    • Conformation of full-length Fip1 within CPSF not resolved
    • Human complex architecture not addressed
  9. 2009 Medium

    Explained why FIP1L1-PDGFRα accumulates: it escapes ubiquitin-mediated degradation, and its protein stability is required for proliferation and STAT5 activation.

    Evidence Ubiquitination Western blots, destabilizing-domain fusion, patient leukocytes

    PMID:19644140

    Open questions at the time
    • Molecular reason for reduced ubiquitination despite Cbl phosphorylation unresolved
    • Single-lab finding
  10. 2009 High

    Connected fusion signaling to cell fate, showing FIP1L1-PDGFRα enforces eosinophil lineage commitment via MEK/p38, C/EBPα and GATA-2 induction, and PU.1 suppression.

    Evidence Murine progenitor transduction, BMT, MEK/p38 inhibitors, shRNA, PU.1 luciferase reporter; plus D842V pan-resistance ENU screen

    PMID:19147501 PMID:19212337

    Open questions at the time
    • Direct transcriptional targets of induced factors not mapped
    • Why eosinophil-specific among myeloid fates incompletely defined
  11. 2012 Medium

    Extended the signaling network to JAK2 and PI3K-dependent NF-κB as required effectors of proliferation, migration, and eosinophil differentiation.

    Evidence JAK2 siRNA/AG490 and dominant-negative IκB/NF-κB inhibition in EOL-1, primary CEL cells, and CD34+ progenitors

    PMID:22271894 PMID:22523564

    Open questions at the time
    • Hierarchy among JAK2, PI3K, NF-κB nodes not fully ordered
    • Single-lab studies
  12. 2014 High

    Defined an oncogene-specific role for SHP2 binding to phosphotyrosine 720 of the fusion in driving ERK signaling and transformation.

    Evidence Tyrosine mutagenesis, SHP2 co-IP and siRNA, Ba/F3, CD34+ progenitors, murine model

    PMID:24618081

    Open questions at the time
    • Why SHP2 dependence is fusion-specific versus wild-type PDGFR not mechanistically explained
  13. 2014 High

    Established hFip1 as essential for stem cell identity by controlling ESC-specific alternative polyadenylation, linking the polyadenylation scaffold to cell-fate gene expression.

    Evidence Mouse ESC knockout/knockdown, PAC-seq/RNA-seq APA profiling, reprogramming and self-renewal assays; FIP1 motif homodimerization in fusion contexts

    PMID:24596251 PMID:24763514

    Open questions at the time
    • Which APA target transcripts drive self-renewal not fully resolved
    • How Fip1-RNA interactions set APA site choice mechanistically unclear
  14. 2015 High

    Resolved a drug-resistance mechanism in which the F604S mutation stabilizes the fusion by recruiting SHP-2 to dampen autophosphorylation and SRC-driven CBL ubiquitination.

    Evidence Pulse-chase stability, mutagenesis, SHP-2 co-IP, SRC inhibition/knockdown

    PMID:25761934

    Open questions at the time
    • Generality of SRC-CBL turnover control across resistance mutants untested
  15. 2022 High

    Delivered the structural and functional architecture of the human CPSF-hFip1 module: two redundant hFip1 copies on CPSF30 ZF4/ZF5 recruit PAP for processivity, and an hFip1 acidic motif binds CstF77 to competitively regulate PAP recruitment.

    Evidence X-ray crystallography of hFip1-CPSF30 and hFip1-CstF77, fluorescence polarization, in vitro polyadenylation, mutagenesis; recombinant CPF NMR showing IDR dynamics; yeast linker analysis

    PMID:21282348 PMID:33122294 PMID:34593603 PMID:36073787

    Open questions at the time
    • How CstF77 competition is regulated during processing in cells unclear
    • Whether the two hFip1 sites are differentially used on specific transcripts unknown
  16. 2021 Medium

    Demonstrated a disease-relevant APA function for hFip1 in inflammation, shortening NLRP3 3'UTR to upregulate NLRP3 under oxidative stress.

    Evidence siRNA in vitro/in vivo kidney injury models, RNA-IP at NLRP3 proximal poly(A) site, 3'RACE/APA profiling; plus STAT5-dependent OSM/CXCL12 paracrine loop in fusion disease

    PMID:23621172 PMID:34011928

    Open questions at the time
    • Breadth of inflammation-relevant APA targets beyond NLRP3 unknown
    • Single-lab findings

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the two functionally distinct activities of FIP1L1 — the CPSF polyadenylation scaffold and the oncogenic fusion N-terminus — are regulated in physiological versus disease contexts, including the in vivo determinants of APA target selection and the full set of post-translational controls, remains unresolved.
  • No comprehensive map of hFip1-controlled APA targets in normal tissues
  • Functional role of CK2 phosphorylation undefined
  • Mechanism integrating signaling, stability, and lineage output in fusion disease incomplete

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 4 GO:0003723 RNA binding 3 GO:0098772 molecular function regulator activity 3 GO:0140098 catalytic activity, acting on RNA 2
Localization
GO:0005634 nucleus 3
Pathway
R-HSA-8953854 Metabolism of RNA 4 R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3 R-HSA-74160 Gene expression (Transcription) 3
Partners
CPSF160CPSF30CSTF77PAP/PAP1PDGFRARNA14SHP2YTH1
Complex memberships
CPF (yeast cleavage and polyadenylation factor)CPSF

Evidence

Reading pass · 27 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 An interstitial deletion on chromosome 4q12 fuses FIP1L1 to PDGFRA, creating a constitutively activated tyrosine kinase (FIP1L1-PDGFRα) that transforms hematopoietic cells. The fusion kinase is inhibited by imatinib (IC50 ~3.2 nM). Resistance is conferred by a T674I point mutation in the PDGFRα kinase domain. Chromosomal analysis, RT-PCR, cell transformation assay (Ba/F3), in vitro kinase inhibition assay The New England Journal of Medicine High 12660384
2003 PKC412 (midostaurin) inhibits FIP1L1-PDGFRα, including the imatinib-resistant T674I mutant, in a murine bone marrow transplant model of FIP1L1-PDGFRα-induced myeloproliferative disease. Murine bone marrow transplantation model, in vitro proliferation assay with Ba/F3 cells transformed by FIP1L1-PDGFRα Cancer Cell High 12781364
2004 Human Fip1 (hFip1, encoded by FIP1L1) is an integral subunit of CPSF. It interacts with poly(A) polymerase (PAP) and contains an arginine-rich RNA-binding motif that preferentially binds U-rich sequence elements on pre-mRNA. Recombinant hFip1 is sufficient to stimulate in vitro polyadenylation activity of PAP in a U-rich element-dependent manner. hFip1, CPSF160, and PAP form a ternary complex in vitro. Co-immunoprecipitation, in vitro polyadenylation assay with recombinant proteins, RNA-binding assay, ternary complex reconstitution The EMBO Journal High 14749727
2006 Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane (JM) domain of PDGFRα, not FIP1L1 itself. The FIP1L1 portion is completely dispensable for kinase activation in vitro and in vivo; truncation of PDGFRα between two conserved tryptophan residues in the JM domain is required for constitutive kinase activation and transforming potential. A complete JM domain is autoinhibitory, but this autoinhibition can be overcome by enforced homodimerization. Deletion mutagenesis, cell transformation assay, in vitro kinase assay, murine bone marrow transplantation Proceedings of the National Academy of Sciences of the USA High 16690743
1995 Yeast Fip1 (the ortholog of FIP1L1) directly interacts with poly(A) polymerase (Pap1) in a 1:1 complex. Fip1 is required for polyadenylation but not cleavage of pre-mRNA in vitro. Fip1 also directly interacts with RNA14, a subunit of cleavage factor I (CF I), through co-immunoprecipitation, thereby tethering Pap1 to CF I to confer substrate specificity. Two-hybrid assay, in vitro reconstitution of 1:1 complex, temperature-sensitive mutant analysis, in vitro 3'-end processing assay, co-immunoprecipitation Cell High 7736590
2001 Yeast Fip1 regulates poly(A) polymerase (Pap1) activity through multiple domains: residues 80–105 bind Pap1 and inhibit its activity by limiting RNA substrate access to Pap1's C-terminal RNA-binding domain (C-RBD); residues 206–220 interact with Yth1 (a CPSF subunit) and are required for specific polyadenylation; residues 105–206 help restrict RNA binding at the C-RBD of Pap1. The C-terminus of Fip1 relieves Fip1-mediated repression of Pap1. Domain deletion mutagenesis, in vitro binding assays, in vitro polyadenylation assay, yeast viability assay Molecular and Cellular Biology High 11238938
2006 Sorafenib is a potent inhibitor of FIP1L1-PDGFRα (wild-type) and the imatinib-resistant FIP1L1-PDGFRα T674I mutant. It inhibits proliferation of transformed Ba/F3 cells and induces apoptosis of EOL-1 cells at nanomolar concentrations, confirmed by Western blot showing direct inhibition of FIP1L1-PDGFRα phosphorylation. In vitro proliferation assay (Ba/F3 cells), apoptosis assay (EOL-1), Western blot for phospho-PDGFRα Blood High 16645167
2007 FIP1L1-PDGFRα induces myeloproliferation in human CD34+ hematopoietic progenitors via activation of PI3K, ERK1/2, and STAT5 signaling pathways. Combined inhibition of PI3K and ERK1/2 significantly reversed FIP1L1-PDGFRα-induced colony formation. Dominant-negative STAT5 partially inhibited colony formation. FIP1L1 residues 30–233 contribute to STAT5 and Akt activation (but not p38/ERK1/2). Retroviral transduction of human CD34+ progenitors, cytokine-independent colony assay, dominant-negative STAT5 expression, pharmacological inhibitors of PI3K and ERK1/2, Western blot signaling analysis Cancer Research High 17440089
2008 Crystal structure of yeast poly(A) polymerase (Pap1) in complex with a peptide of Fip1 residues 80–105 at 2.6 Å resolution. The Fip1 peptide binds the outer surface of the C-terminal domain of Pap1. A Pap1 mutant (V498Y, C485R) designed from the structure cannot bind Fip1 but retains full polymerase activity and is lethal in yeast. Fip1 is largely disordered in the absence of Pap1. X-ray crystallography (2.6 Å), site-directed mutagenesis, yeast viability assay, analytical ultracentrifugation, circular dichroism, limited proteolysis Biochemistry High 18537269
2009 FIP1L1-PDGFRα and TEL-PDGFRβ fusion proteins escape ubiquitination and proteasomal degradation unlike their wild-type counterparts. Ubiquitination of FIP1L1-PDGFRα is markedly reduced despite Cbl phosphorylation. Protein stability of the fusion is critical for efficient stimulation of cell proliferation and STAT5 activation, demonstrated by an inducible destabilizing domain fusion experiment. Western blot for ubiquitination and protein levels in Ba/F3 cells and patient leukocytes, destabilizing domain (DD) fusion approach, STAT5 phosphorylation assay Haematologica Medium 19644140
2009 FIP1L1-PDGFRα confers eosinophil lineage commitment on hematopoietic stem/progenitor cells by activating MEK1/2 and p38 MAPK more intensely than TEL-PDGFRβ. FIP1L1-PDGFRα augments expression of C/EBPα, GATA-1, and GATA-2 while suppressing PU.1 activity via Ras signaling. shRNA knockdown of C/EBPα, GATA-2, and dominant-negative GATA inhibited FIP1L1-PDGFRα-induced eosinophil development. Retroviral transduction of murine hematopoietic progenitor subsets, cytokine-independent replating assay, bone marrow transplantation, pharmacological MEK/p38 inhibition, shRNA knockdown, luciferase reporter for PU.1 activity, RT-PCR for transcription factor expression The Journal of Biological Chemistry High 19147501
2009 FIP1L1-PDGFRα D842V mutation is pan-resistant to sorafenib, imatinib, dasatinib, and PKC412 in vitro. This mutant emerged clinically under sorafenib therapy for T674I-mutant disease, and was identified as a major sorafenib-resistant mutant by ENU mutagenesis screen. ENU-mutagenesis screen, in vitro proliferation assays with Ba/F3 cells expressing D842V mutant, clinical case report with molecular confirmation Leukemia Medium 19212337
2005 hFip1 (FIP1L1 protein) interacts specifically with the U-rich upstream element of the HPV-16 early polyadenylation signal and enhances polyadenylation at that site. RNA pulldown/interaction assay (in vitro binding), polyadenylation signal analysis, deletion mapping Journal of Virology Medium 15767428
2011 Yeast Fip1 contains a flexible linker region (middle of the protein) required for efficient mRNA polyadenylation. Removal or replacement of the linker reduces polyadenylation efficiency. The linker provides a platform for interactions with other polyadenylation machinery components. A fusion protein of Pap1 directly tethered to Fip1 is fully functional, and direct tethering of Pap1 to RNA increases the rate of poly(A) addition. In vitro polyadenylation assay, yeast viability assay, deletion/replacement mutagenesis, Pap1-Fip1 fusion protein functional test RNA High 21282348
2014 Fip1 is essential for embryonic stem cell (ESC) self-renewal and somatic cell reprogramming. Fip1 promotes stem cell maintenance by activating ESC-specific alternative polyadenylation (APA) profiles through Fip1-RNA interactions and APA site distance. Loss of Fip1 disrupts expression of critical self-renewal factors. Genetic knockout/knockdown in mouse ESCs, RNA-seq/PAC-seq for APA profiling, somatic reprogramming assay, self-renewal colony assay The EMBO Journal High 24596251
2012 FIP1L1-PDGFRα activates JAK2, and JAK2 is required for FIP1L1-PDGFRα-driven cellular proliferation and migration. JAK2 inhibition (siRNA or AG490) in EOL-1 and primary FIP1L1-PDGFRα+ CEL cells reduces proliferation, induces apoptosis, and blocks IL-5-induced migration. JAK2 mediates STAT3 (but not STAT5) activation and also activates PI3K/Akt and NF-κB downstream. siRNA knockdown of JAK2, pharmacological inhibition (AG490), Western blot for signaling, proliferation and apoptosis assays, migration assay, patient primary cells PLoS One Medium 22523564
2012 FIP1L1-PDGFRα activates NF-κB via PI3K. NF-κB is required for FIP1L1-PDGFRα-driven eosinophil differentiation from human CD34+ progenitors, including expression of IL-5Rα and eosinophil peroxidase. Bortezomib and the IκB kinase inhibitor BMS-345541 block proliferation of EOL-1 cells. Lentiviral transduction of human CD34+ progenitors, PI3K inhibitor, dominant-negative IκB expression, pharmacological NF-κB inhibition, gene expression microarray Haematologica Medium 22271894
2014 SHP2 tyrosine phosphatase binds directly to tyrosine 720 of FIP1L1-PDGFRα and is required for ERK signaling and cell transformation. Mutation of Y720 or SHP2 knockdown reduces proliferation and ERK (but not STAT5) signaling in Ba/F3 cells and in human CD34+ progenitors. SHP2 is not required for wild-type PDGFR-driven ERK activation, indicating an oncogene-specific shift in SHP2 function. Site-directed mutagenesis (12 tyrosine residues), SHP2 siRNA knockdown, in vivo murine myeloproliferation assay, human CD34+ progenitor assay, co-immunoprecipitation (SHP2 binding to Y720) Molecular Oncology High 24618081
2014 In FIP1L1-RARA fusion, the FIP1 motif of FIP1L1 is required for homodimerization and transcriptional repressor activity. In FIP1L1-PDGFRα, the C-terminal PDGFRα portion can form homodimers independently, making FIP1L1 dispensable for constitutive kinase activation, but FIP1L1 contributes to complete IL-3 independence of transformed cells. Deletion mutant analysis, hematopoietic cell transformation assay (BAF-B03), cytokine independence assay Annals of Hematology Medium 24763514
2015 The F604S mutation in FIP1L1-PDGFRα stabilizes the fusion protein by creating a binding site for the SHP-2 phosphatase domain, reducing autophosphorylation and consequently reducing SRC activation. SRC normally promotes FIP1L1-PDGFRα degradation via CBL ubiquitination; reduced SRC activation thus prolongs protein half-life. SRC inhibition or knockdown phenocopies the protein stabilization seen with F604S. Pulse-chase protein stability assay, site-directed mutagenesis, co-immunoprecipitation (SHP-2 binding), SRC inhibition and knockdown, Western blot for autophosphorylation and CBL Leukemia High 25761934
2020 Human CPSF30 ZF4-ZF5 binds hFip1 with 1:2 stoichiometry (one hFip1 molecule per zinc finger, ZF4 and ZF5). Crystal structure at 1.9 Å reveals a conserved binding mode for each ZF. ZF4 has higher affinity for hFip1 (Kd = 1.8 nM). Two copies of the catalytic module of PAP are recruited by the CPSF30-hFip1 complex in vitro, and both hFip1 binding sites in CPSF30 can support polyadenylation. X-ray crystallography (1.9 Å), fluorescence polarization binding assay, mutagenesis, in vitro polyadenylation assay Genes & Development High 33122294
2021 Yeast Fip1, within the reconstituted ~850 kDa CPF complex, anchors poly(A) polymerase Pap1 via an interaction with zinc finger 4 of Yth1. The intrinsically disordered region (IDR) of Fip1 connecting the Yth1- and Pap1-binding sites remains highly dynamic within CPF, as demonstrated by NMR spectroscopy on selectively labeled Fip1 incorporated into the recombinant complex. Fully recombinant CPF reconstitution, NMR spectroscopy (selective isotope labeling), genetic interaction (Fip1-Yth1 ZF4 interaction mapped) Genes & Development High 34593603
2022 CPSF contains two copies of hFip1, each binding to ZF4 and ZF5 of CPSF30 (crystal structures reported). The two hFip1 copies are functionally redundant in recruiting one copy of PAP, increasing processivity of RNA polyadenylation. hFip1 interacts with CstF77 via a short motif in its N-terminal 'acidic' region; CstF77 competitively inhibits CPSF-dependent PAP recruitment and polyadenylation. X-ray crystallography (hFip1-CPSF30 and hFip1-CstF77 complexes), in vitro polyadenylation assay, mutagenesis eLife High 36073787
2021 FIP1L1 (hFip1) promotes 3'UTR shortening of NLRP3 mRNA via its arginine-rich domain binding to the proximal poly(A) site (pPAS) of NLRP3 mRNA, thereby upregulating NLRP3 expression and amplifying inflammation in kidney injury. FIP1L1 is upregulated by oxidative stress and is required for oxidative stress-induced NLRP3 upregulation. siRNA knockdown (in vitro and in vivo UUO/IRI models), RNA-IP (FIP1L1 binding to NLRP3 pPAS), 3'RACE/APA profiling, Western blot, inflammation/fibrosis functional assays Cell Death & Disease Medium 34011928
2006 Yeast Fip1 is phosphorylated in vitro by protein kinase CK2 (but not CK1) at serine residues 73 and 77, as identified by MALDI-MS. CK2α' and holoenzyme phosphorylate Fip1 with Km of ~1.3–1.4 µM. In vitro kinase assay with recombinant CK2, MALDI-MS identification of phosphorylation sites Molecular and Cellular Biochemistry Medium 16496213
2007 FIP1L1-PDGFRα induces proliferation of EOL-1 eosinophilic leukemia cells through upregulation of c-Myc via ERK and JNK signaling pathways. Imatinib inhibits proliferation and decreases c-Myc, phospho-ERK, and phospho-JNK. MEK inhibitor (U0126) and JNK inhibitor (SP600125) also reduce c-Myc expression and proliferation. FIP1L1-PDGFRα is not required for inhibition of eosinophil differentiation. Western blot, pharmacological inhibitors (imatinib, U0126, SP600125), RT-PCR for c-Myc in EOL-1 cells Biochemical and Biophysical Research Communications Medium 18086564
2013 FIP1L1-PDGFRα (F/P) upregulates oncostatin M (OSM) expression in a STAT5-dependent manner. OSM secreted by neoplastic eosinophils stimulates stromal cell proliferation and upregulates SDF-1/CXCL12 production in fibroblasts, which in turn induces migration of EOL-1 cells—constituting a paracrine loop contributing to tissue fibrosis and eosinophil accumulation. Lentiviral F/P transduction of cell lines, doxycycline-inducible F/P in Ba/F3, STAT5 inhibition, immunohistochemistry of patient material, gene expression analysis, proliferation and chemotaxis assays Allergy Medium 23621172

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2003 A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. The New England journal of medicine 1314 12660384
2003 CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 298 12842979
2004 FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 247 15284118
2003 The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 213 15070659
2004 Human Fip1 is a subunit of CPSF that binds to U-rich RNA elements and stimulates poly(A) polymerase. The EMBO journal 209 14749727
2009 Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 203 19262599
2003 PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer cell 187 12781364
2007 Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 159 17299092
2007 The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 156 17666373
2014 Fip1 regulates mRNA alternative polyadenylation to promote stem cell self-renewal. The EMBO journal 139 24596251
2004 Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 133 14973504
2007 Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 126 17377585
1995 The FIP1 gene encodes a component of a yeast pre-mRNA polyadenylation factor that directly interacts with poly(A) polymerase. Cell 123 7736590
2008 Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 122 18843283
2006 Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 119 16645167
2006 FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leukemia research 107 16406016
2006 Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proceedings of the National Academy of Sciences of the United States of America 101 16690743
2009 FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 99 19212337
2005 The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 99 16030188
2003 The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 85 14630792
2007 KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. The Journal of allergy and clinical immunology 81 17628645
2008 A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. British journal of haematology 67 18307562
2007 Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer research 62 17440089
2006 The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 62 16418325
2005 A 57-nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFip1, CstF-64, hnRNP C1/C2, and polypyrimidine tract binding protein. Journal of virology 62 15767428
2006 Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. British journal of haematology 60 16409293
2020 Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients. American journal of hematology 57 32720700
2004 The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Current opinion in hematology 57 14676627
2001 Fip1 regulates the activity of Poly(A) polymerase through multiple interactions. Molecular and cellular biology 57 11238938
2005 The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica 51 15921374
2012 Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells. Clinical cancer research : an official journal of the American Association for Cancer Research 48 22447844
2012 ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB. Haematologica 44 22271894
2009 The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation. Haematologica 43 19644140
2004 FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica 41 15257945
2009 Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Leukemia research 40 19144405
2019 The polyadenylation factor FIP1 is important for plant development and root responses to abiotic stresses. The Plant journal : for cell and molecular biology 38 31111599
2010 FIP1/RCP binding to Golgin-97 regulates retrograde transport from recycling endosomes to the trans-Golgi network. Molecular biology of the cell 38 20610657
2021 Glioma glycolipid metabolism: MSI2-SNORD12B-FIP1L1-ZBTB4 feedback loop as a potential treatment target. Clinical and translational medicine 36 34047477
2007 The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia 36 17495975
2008 Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions. Leukemia 35 18987650
2006 Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leukemia research 35 16682077
2014 Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. Experimental hematology 34 24407160
2005 Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement. Journal of pediatric hematology/oncology 33 16344672
2006 The Rab11-FIP1/RCP gene codes for multiple protein transcripts related to the plasma membrane recycling system. Biochimica et biophysica acta 30 16920206
2021 Alternative polyadenylation trans-factor FIP1 exacerbates UUO/IRI-induced kidney injury and contributes to AKI-CKD transition via ROS-NLRP3 axis. Cell death & disease 29 34011928
2006 Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leukemia research 29 16406018
2006 Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity. The European respiratory journal 28 16387954
2012 Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL. PloS one 27 22523564
2009 FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. The Journal of biological chemistry 27 19147501
2008 Structure of yeast poly(A) polymerase in complex with a peptide from Fip1, an intrinsically disordered protein. Biochemistry 27 18537269
2016 Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. Oncotarget 26 27120808
2008 The molecular anatomy of the FIP1L1-PDGFRA fusion gene. Leukemia 26 18987651
2013 The rab11 effector protein FIP1 regulates adiponectin trafficking and secretion. PloS one 25 24040321
2008 Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Experimental hematology 24 18619723
2021 Rab11-FIP1 mediates epithelial-mesenchymal transition and invasion in esophageal cancer. EMBO reports 23 33403789
2017 Structural basis of jasmonate-amido synthetase FIN219 in complex with glutathione S-transferase FIP1 during the JA signal regulation. Proceedings of the National Academy of Sciences of the United States of America 21 28223489
2007 The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. Leukemia 21 17914408
2014 Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin. Molecular cancer 20 24472312
2009 A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy 20 19210352
2014 FIP1L1 presence in FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes to the pathogenesis of distinct types of leukemia. Annals of hematology 19 24763514
2006 Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia. Methods in molecular medicine 19 16502585
2011 A flexible linker region in Fip1 is needed for efficient mRNA polyadenylation. RNA (New York, N.Y.) 17 21282348
2010 Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study. Hematological oncology 17 19728396
2021 FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction. Stroke 16 34304603
2021 Dynamics in Fip1 regulate eukaryotic mRNA 3' end processing. Genes & development 16 34593603
2014 The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V. Molecular oncology 16 24618081
2009 FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia. BMC blood disorders 16 19187542
2009 Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome. Cancer science 16 19671059
2014 Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. Journal of hematology & oncology 15 24669761
2007 FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. Leukemia 15 17215855
2007 Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy. European journal of haematology 15 18028420
2020 Molecular mechanism for the interaction between human CPSF30 and hFip1. Genes & development 14 33122294
2010 FIP1L1/PDGFR alpha-associated systemic mastocytosis. International archives of allergy and immunology 14 20523072
2022 Fip1 is a multivalent interaction scaffold for processing factors in human mRNA 3' end biogenesis. eLife 13 36073787
2008 FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome. Blood 13 18539901
2017 Rab11-FIP1 phosphorylation by MARK2 regulates polarity in MDCK cells. Cellular logistics 12 28396819
2015 F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance. Leukemia 12 25761934
2013 The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα. PloS one 12 24009732
2006 Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy. International journal of hematology 11 16513534
2021 Rab11-FIP1 and Rab11-FIP5 Regulate pIgR/pIgA Transcytosis through TRIM21-Mediated Polyubiquitination. International journal of molecular sciences 10 34638806
2015 Generalized Eruptive Histiocytosis Associated With FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia. JAMA dermatology 10 25923837
2014 Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells. Oncotarget 10 25431951
2013 Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia. Allergy 10 23621172
2007 A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint. The Journal of molecular diagnostics : JMD 10 17591942
2014 Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy. European journal of haematology 9 24460680
2007 A multicenter analysis of the FIP1L1-alphaPDGFR fusion gene in Japanese idiopathic hypereosinophilic syndrome: an aberrant splicing skipping the alphaPDGFR exon 12. Annals of hematology 9 17701174
2013 A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease. The American journal of surgical pathology 8 23232855
2011 Comparative proteomic analysis of blood eosinophils reveals redox signaling modifications in patients with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia. Journal of proteome research 8 21302907
2009 The FIP-1 like polyadenylation factor in trypanosomes and the structural basis for its interaction with CPSF30. Biochemical and biophysical research communications 8 19338765
2008 Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations. Leukemia research 8 19118897
2021 Myeloid Sarcoma Type of Acute Promyelocytic Leukemia With a Cryptic Insertion of RARA Into FIP1L1: The Clinical Utility of NGS and Bioinformatic Analyses. Frontiers in oncology 7 34249738
2017 A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia. Cancer genetics 7 29025601
2015 Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. Experimental hematology & oncology 7 26457233
2014 Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis. Experimental hematology 7 24486648
2014 FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia: A Low-Burden Disease with Dramatic Response to Imatinib - A Report of 5 Cases from South India. Turkish journal of haematology : official journal of Turkish Society of Haematology 7 24764730
2008 FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. Chinese medical journal 7 18706197
2007 Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity. International journal of hematology 7 17988989
2007 Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha. Biochemical and biophysical research communications 7 18086564
2006 Fip1--an essential component of the Saccharomyces cerevisiae polyadenylation machinery is phosophorylated by protein kinase CK2. Molecular and cellular biochemistry 6 16496213
2005 FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia. Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 6 16089297

Missed literature

Know a paper Affinage missed for FIP1L1? Flag it for the maintainers and the community.

No submissions yet.